Pediatric Clinics of North America - CIPERJ

320 GOLDENBERG & BERNARD
[10] Hoyer PF, Gonda S, Barthels M, et al. Thromboembolic complications in children with nephritic
syndrome. Risk and incidence. Acta Paediatr Scand 1986;75:804–10.
[11] Lewy PR, Jao W. Nephrotic syndrome in association with renal vein thrombosis in infancy.
J Pediatr 1974;85:359–65.
[12] Goldenberg NA, Knapp-Clevenger R, Hays T, et al. Lemierre’s and Lemierre’s-like syndromes
in children: survival and thromboembolic outcomes. Pediatrics 2005;116:e543–8.
[13] Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Laboratory testing for thrombophilia
in pediatric patients. On behalf of the Subcommittee for Perinatal and Pediatric
Thrombosis of the Scientific and Standardization Committee of the International Society
on Threombosis and Haemostasis (ISTH). Thromb Haemost 2002;88:155–6.
[14] Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: the Seventh
ACCP Conference on Antithrombotic and Thrombotic Therapy. Chest 2004;126(Suppl 3):
645S–87S.
[15] Manco-Johnson M. How I treat venous thrombosis in children. Blood 2006;107:21–9.
[16] Nohe N, Flemmer A, Rumler R, et al. The low molecular weight heparin dalteparin for prophylaxis
and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999;
158:S134–9.
[17] Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective
cohort study. Pediatr Res 1994;35:78–83.
[18] Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in
the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260–4.
[19] Kearon C, Ginsberg JS, Julina JA, et al. Comparison of fixed-dose weight-adjusted unfractionated
heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
JAMA 2006;296:935–42.
[20] Berube C, Mitchell L, Silverman E, et al. The relationship of antiphospholipid antibodies to
thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional
study. Pediatr Res 1998;44:351–6.
[21] Monagle P, Andew M. Acquired disorders of hemostasis. In: Nathan DG, Stuart H,
Orkin A, editors. Nathan and Oski’s hematology of infancy and childhood. 6th edition.
Philadelpia: Saunders; 2003.
[22] Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy
with conventional-intensity warfarin therapy for long-term prevention of recurrent venous
thromboembolism. N Engl J Med 2003;349:631–9.
[23] Kovacs MJ. Long-term low-dose warfarin use is effective in the prevention of recurrent venous
thromboembolism: no. J Thromb Haemost 2004;2:1041–3.
[24] Goldenberg NA, Knapp-Clevenger R, Durham JD, et al. A thrombolytic regimen for highrisk
deep venous thrombosis may substantially reduce the risk of post-thrombotic syndrome
in children. Blood 2007;110:45–53.
[25] Vukovich T, Auberger K, Weil J, et al. Replacement therapy for a homozygous protein C
deficiency state using a concentrate of human protein C and S. Br J Haematol 1988;70:435–40.
[26] Dreyfus M, Masterson M, David M, et al. Replacement therapy with a monoclonal antibody
purified protein C concentrate in newborns with severe congenital protein C deficiency.
Semin Thromb Hemost 1995;21:371–81.
[27] Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and
neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991;325:
1565–8.
[28] Muller FM, Ehrenthal W, Hafner G, et al. Purpura fulminans in severe congenital protein
C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr
1996;155:20–5.
[29] de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein
C concentrate in children with severe meningococcal sepsis and purpura fulminans:
a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med
2003;31:1839–47.